AML Clinical Trials in Dallas, Texas
10 recruitingDallas, Texas
Showing 1–10 of 10 trials
Recruiting
Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled45 locationsNCT06001788
Recruiting
Phase 3
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Acute Myeloid Leukemia (AML)
Kura Oncology, Inc.1,300 enrolled39 locationsNCT07007312
Recruiting
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Hematologic MalignanciesInherited Disorders of MetabolismInherited Abnormalities of Platelets+2 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 1
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
AMLMyelodysplastic SyndromesALL, Adult
TScan Therapeutics, Inc.75 enrolled15 locationsNCT05473910
Recruiting
Phase 1
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled15 locationsNCT05768932
Recruiting
Phase 1
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Acute Myeloid LeukemiaMyeloid SarcomaAcute Myeloid Leukemia, in Relapse+7 more
Kura Oncology, Inc.420 enrolled44 locationsNCT05735184
Recruiting
Phase 1
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
AML With Gene Mutations
Lomond Therapeutics Holdings, Inc.150 enrolled23 locationsNCT06366789
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 1
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Acute Myeloid Leukemia (AML)
Aptevo Therapeutics39 enrolled7 locationsNCT06634394
Recruiting
Phase 1
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Hodgkin LymphomaAMLMDS+8 more
Therapeutic Advances in Childhood Leukemia Consortium54 enrolled31 locationsNCT05476770